|
1
|
Shinohara N and Abe T: Prognostic factors
and risk classifications for patients with metastatic renal cell
carcinoma. Int J Urol. 22:888–897. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N
Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Motzer RJ, Escudier B, Oudard S, Hutson
TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA,
Hollaender N, et al: Efficacy of everolimus in advanced renal cell
carcinoma: A double-blind, randomised, placebo-controlled phase III
trial. Lancet. 372:449–456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rini BI, Escudier B, Tomczak P, Kaprin A,
Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME,
Rusakov IG, et al: Comparative effectiveness of axitinib versus
sorafenib in advanced renal cell carcinoma (AXIS): A randomised
phase 3 trial. Lancet. 378:1931–1939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Motzer RJ, Hutson TE, Cella D, Reeves J,
Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et
al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hudes G, Carducci M, Tomczak P, Dutcher J,
Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi
I, et al: Temsirolimus, interferon alfa, or both for advanced
renal-cell carcinoma. N Engl J Med. 356:2271–2281. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ninomiya N, Tamada S, Kato M, Yamasaki T,
Iguchi T and Nakatani T: Prolonging survival in metastatic renal
cell carcinoma patients treated with targeted anticancer agents: A
single-center experience of treatment strategy modifications. Can J
Urol. 22:7798–7804. 2015.PubMed/NCBI
|
|
9
|
Kondo T, Takagi T, Kobayashi H, Iizuka J,
Nozaki T, Hashimoto Y, Ikezawa E, Yoshida K, Omae K and Tanabe K:
Superior tolerability of altered dosing schedule of sunitinib with
2-weeks-on and 1-week-off in patients with metastatic renal cell
carcinoma-comparison to standard dosing schedule of 4-weeks-on and
2-weeks-off. Jpn J Clin Oncol. 44:270–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miyake H, Miyazaki A, Harada K and
Fujisawa M: Assessment of efficacy, safety and quality of life of
110 patients treated with sunitinib as first-line therapy for
metastatic renal cell carcinoma: Experience in real-world clinical
practice in Japan. Med Oncol. 31:9782014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Akaza H, Oya M, Iijima M, Hyodo I, Gemma
A, Itoh H, Adachi M, Okayama Y, Sunaya T and Inuyama L: A
large-scale prospective registration study of the safety and
efficacy of sorafenib tosylate in unresectable or metastatic renal
cell carcinoma in Japan: Results of over 3200 consecutive cases in
post-marketing all-patient surveillance. Jpn J Clin Oncol.
45:953–962. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shinohara N, Obara W, Tatsugami K and
Naito S, Kamba T, Takahashi M, Murai S, Abe T, Oba K and Naito S:
Prognosis of Japanese patients with previously untreated metastatic
renal cell carcinoma in the era of molecular-targeted therapy.
Cancer Sci. 106:618–626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Motzer RJ, Bacik J, Murphy BA, Russo P and
Mazumdar M: Interferon-alfa as a comparative treatment for clinical
trials of new therapies against advanced renal cell carcinoma. J
Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI,
Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, et al: The
International Metastatic Renal Cell Carcinoma Database Consortium
model as a prognostic tool in patients with metastatic renal cell
carcinoma previously treated with first-line targeted therapy: A
population-based study. Lancet Oncol. 16:293–300. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili
R, Bjarnason GA, et al: Overall survival and updated results for
sunitinib compared with interferon alfa in patients with metastatic
renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shinohara N, Nonomura K, Abe T, Maruyama
S, Kamai T, Takahashi M, Tatsugami K, Yokoi S, Deguchi T, Kanayama
H, et al: A new prognostic classification for overall survival in
Asian patients with previously untreated metastatic renal cell
carcinoma. Cancer Sci. 103:1695–1700. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Naito S, Yamamoto N, Takayama T, Muramoto
M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T,
Hoshi S, et al: Prognosis of Japanese metastatic renal cell
carcinoma patients in the cytokine era: A cooperative group report
of 1463 patients. Eur Urol. 57:317–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patil S, Figlin RA, Hutson TE, Michaelson
MD, Négrier S, Kim ST, Huang X and Motzer RJ: Prognostic factors
for progression-free and overall survival with sunitinib targeted
therapy and with cytokine as first-line therapy in patients with
metastatic renal cell carcinoma. Ann Oncol. 22:295–300. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McKay RR, Kroeger N, Xie W, Lee JL, Knox
JJ, Bjarnason GA, MacKenzie MJ, Wood L, Srinivas S, Vaishampayan
UN, et al: Impact of bone and liver metastases on patients with
renal cell carcinoma treated with targeted therapy. Eur Urol.
65:577–584. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Motzer RJ, Escudier B, Tomczak P, Hutson
TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J,
Hariharan S, et al: Axitinib versus sorafenib as second-line
treatment for advanced renal cell carcinoma: Overall survival
analysis and updated results from a randomised phase 3 trial.
Lancet Oncol. 14:552–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Motzer RJ, Bukowski RM, Figlin RA, Hutson
TE, Michaelson MD, Kim ST, Baum CM and Kattan MW: Prognostic
nomogram for sunitinib in patients with metastatic renal cell
carcinoma. Cancer. 113:1552–1558. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wahlgren T, Harmenberg U, Sandstrom P,
Sandström P, Lundstam S, Kowalski J, Jakobsson M, Sandin R and
Ljungberg B: Treatment and overall survival in renal cell
carcinoma: A Swedish population-based study (2000–2008). Br J
Cancer. 108:1541–1549. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kroeger N, Pantuck AJ, Wells JC, Lawrence
N, Broom R, Kim JJ, Srinivas S, Yim J, Bjarnason GA, Templeton A,
et al: Characterizing the impact of lymph node metastases on the
survival outcome for metastatic renal cell carcinoma patients
treated with targeted therapies. Eur Urol. 68:506–515. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yuasa T, Inoshita N, Saiura A, Yamamoto S,
Urakami S, Masuda H, Fujii Y, Fukui I, Ishikawa Y and Yonese J:
Clinical outcome of patients with pancreatic metastases from renal
cell cancer. BMC Cancer. 15:462015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grassi P, Verzoni E, Mariani L, De Braud
F, Coppa J, Mazzaferro V and Procopio G: Prognostic role of
pancreatic metastases from renal cell carcinoma: Results from an
Italian center. Clin Genitourin Cancer. 11:484–488. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kalra S, Atkinson BJ, Matrana MR, Matin
SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, et al:
Prognosis of patients with metastatic renal cell carcinoma and
pancreatic metastases. BJU Int. 117:761–765. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chrom P, Stec R, Bodnar L and Szczylik C:
Prognostic significance of pancreatic metastases from renal cell
carcinoma in patients treated with tyrosine kinase inhibitors.
Anticancer Res. 38:359–365. 2018.PubMed/NCBI
|
|
29
|
Gerlinger M, Rowan AJ, Horswell S, Math M,
Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N,
Stewart A, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alt AL, Boorjian SA, Lohse CM, Costello
BA, Leibovich BC and Blute ML: Survival after complete surgical
resection of multiple metastases from renal cell carcinoma. Cancer.
117:2873–2882. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Naito S, Kinoshita H, Kondo T, Shinohara
N, Kasahara T, Saito K, Takayama T, Masumori N, Takahashi W,
Takahashi M, et al: Prognostic factors of patients with metastatic
renal cell carcinoma with removed metastases: A multicenter study
of 556 patients. Urology. 82:846–851. 2013. View Article : Google Scholar : PubMed/NCBI
|
